Judith K. Evans

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 776 citations

Medicine, Pharmacology, Pharmacotherapy +17

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

S. Poli-Bigelli, José Rodrigues-Pereira, Alexandra D. Carides et al. · Cancer · 2003 · 566 citations

Medicine, Oncology, Pharmacology +17

A Randomized, Double-Blind Comparison of the NK1 Antagonist, Aprepitant, Versus Ondansetron for the Prevention of Postoperative Nausea and Vomiting

Tong J. Gan, Christian C. Apfel, Anthony L. Kovac et al. · Anesthesia & Analgesia · 2007 · 221 citations

Medicine, Pharmacology, Pharmacotherapy +17

Establishing the dose of the oral NK₁ antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla et al. · Cancer · 2003 · 216 citations · Full text

Medicine, Oncology, Pharmacology +17

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

Richard H. Hunt, S. E. Harper, Douglas J. Watson et al. · The American Journal of Gastroenterology · 2003 · 163 citations

Pharmacy, Pharmacology, Pharmacotherapy +17